Key result
Newly developed stable hERG-expressing HEK293T cell line demonstrates robust channel function in ~94% of cells.
Why the study?
The hERG potassium channel is critical for cardiac repolarization and pre-clinical drug safety screening, requiring a robust, stable cell line with uniform, high expression for high-throughput assessments.
The established stable hERG-expressing HEK293T cell line demonstrates canonical channel function and physiological sensitivity, providing a standardized platform for pre-clinical drug-induced long QT syndrome risk evaluation.
Offers a robust in vitro tool for pre-clinical drug safety screening; leaves open whether this high-.
The hERG potassium channel is critical for cardiac ventricular repolarization and a core target in pre-clinical drug safety screening. A robust, stable cell line with uniform, high hERG expression is essential for high-throughput assessments. In this study, we established a functional stable HEK293T cell line with high hERG expression. The hERG gene was subcloned into Lenti-HA-hERG-P2A-EGFP plasmid, in which GFP serves as a selection marker via a P2A self-cleaving peptide. GFP-positive monoclonal cells were isolated by fluorescence-activated cell sorting (FACS). Confocal imaging confirmed that hERG localized predominantly to the cell membrane, consistent with its physiological role. Manual patch-clamp revealed canonical hERG current properties: a small, stable current during depolarization to 20 mV, followed by a large outward tail current upon repolarization to −40 mV-a hallmark of hERG channel gating. Automated patch-clamp (APC)-based current profiling showed 93.5% of stable hERG cells exhibited peak tail currents >50 pA (87% > 100 pA, with 49.5% > 400 pA), whereas 100% of blank HEK293T cells showed peak tail currents < 50 pA. Pharmacological validation with E-4031 demonstrated concentration-dependent inhibition of hERG currents, with an IC50 of 29.8 nM, which is consistent with literature-reported values. The stable hERG-expressing HEK293T cell line developed here exhibits consistent hERG expression, canonical channel function, and physiological sensitivity to hERG blockers. When paired with high-throughput APC systems, this cell model provides a robust, standardized platform for pre-clinical drug-induced hERG inhibition evaluation, aiding early detection of long QT syndrome risks and safer drug development.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) studied this question. A newly developed stable hERG-expressing HEK293T cell line exhibited robust channel function, with 93.5% of cells showing peak tail currents >50 pA and an E-4031 inhibition IC50 of 29.8 nM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: